Management of chronic pancreatitis. Focus on enzyme replacement therapy.
The goals of treatment with pancreatic extracts in patients with chronic relapsing pancreatitis are twofold: pain relief and control of maldigestion caused by exocrine pancreatic insufficiency. Experience with the use of pancreatic enzymes for analgesic purposes suggests that the less severe the pain, the greater the analgesic effect of these enzymes. However, the number of trials, as well as the number of patients treated, is fairly small and more studies in larger patient populations are needed. The use of pancreatic enzymes for maldigestion owing to exocrine pancreatic insufficiency which is secondary to chronic pancreatitis, pancreatectomy, cystic fibrosis, or GI bypass surgery incurs several problems. These problems are primarily caused by gastric inactivation of the enzymes, low enzyme activity of many commercial preparations and/or poor patient compliance. Treatment with conventional enzyme products (powdered extracts, enteric-coated tablets or capsules) has been disappointing. At best, results were inconsistent, showing a high degree of individual variation. The introduction of enzyme preparations in the form of pH-sensitive enteric-coated microspheres in hard gelatin capsules represents a significant advance. These microspheres are superior to conventional enzyme preparations in improving the symptoms of pancreatic insufficiency, particularly steatorrhea, where low doses of microspheres are as effective as large doses of conventional enzyme preparations. Steatorrhea, however, is rarely completely resolved. In cases refractory to therapy, treatment with the combination of pH-sensitive enteric-coated microspheres and H2-antagonists or prostaglandins has met with some success.
Dobrilla
G
G
Division of Gastroenterology, General Regional Hospital, Bolzano, Italy.
D002908:Chronic Disease; D057487:Enzyme Therapy; D004798:Enzymes / Q000009:adverse effects; D006801:Humans; D010179:Pancreas / Q000201:enzymology; D010184:Pancreatic Extracts / Q000009:adverse effects / Q000627:therapeutic use; D010195:Pancreatitis / Q000188:drug therapy* / Q000201:enzymology
D004798:Enzymes; D010184:Pancreatic Extracts